Free Trial

Vaxcyte (PCVX) FDA Events

Vaxcyte logo
$35.93 -0.31 (-0.86%)
Closing price 04:00 PM Eastern
Extended Trading
$35.92 -0.01 (-0.03%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
FDA Events for Vaxcyte (PCVX)

This section highlights FDA-related milestones and regulatory updates for drugs developed by Vaxcyte (PCVX). Over the past two years, Vaxcyte has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as VAX-24 and VAX-31. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

Vaxcyte's Drugs in FDA Review

VAX-24 - FDA Regulatory Timeline and Events

VAX-24 is a drug developed by Vaxcyte for the following indication: Pneumococcal Conjugate Vaccine (PCV). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

VAX-31 - FDA Regulatory Timeline and Events

VAX-31 is a drug developed by Vaxcyte for the following indication: For the Prevention of Invasive Pneumococcal Disease. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Vaxcyte FDA Events - Frequently Asked Questions

In the past two years, Vaxcyte (PCVX) has not received FDA approval for any therapies. However, the company does have drugs under review or in active clinical development.

In the past two years, Vaxcyte (PCVX) has reported FDA regulatory activity for the following drugs: VAX-31 and VAX-24.

The most recent FDA-related event for Vaxcyte occurred on March 31, 2025, involving VAX-24. The update was categorized as "Top-line results," with the company reporting: "Vaxcyte, Inc. shared positive topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, the Company's 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® (PCV20) in healthy infants."

Current therapies from Vaxcyte in review with the FDA target conditions such as:

  • For the Prevention of Invasive Pneumococcal Disease - VAX-31
  • Pneumococcal Conjugate Vaccine (PCV) - VAX-24

More FDA Event Resources from MarketBeat

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

This page (NASDAQ:PCVX) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners